Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Reading the tea leaves...
View:
Post by Eoganacht on Mar 08, 2022 12:09pm

Reading the tea leaves...

Theralase has released 7 quarterly newsletters so far. 3 of them were released before the market opened on Monday and 4 of them were released either after the market closed on Monday or before it opened on Tuesday.
Comment by Oilminerdeluxe on Mar 08, 2022 12:21pm
Anyone of you fine gentlemen getting through when calling the company these days? I think they see my number and say: 'Oh no,  it's that greedy Swede again' and refuse to answer...
Comment by 99942Apophis on Mar 08, 2022 12:38pm
One time when I had a conversation with Kristina she brought up the subject of news releases and stated she didn't want their news release timings to become predictable. You saw my possible time frame from Feb. 22 to March 11 so we are still within that zone I take it your suggestion would take aim at this coming Monday! If so that would be highly probable according to your observation.  ...more  
Comment by Eoganacht on Mar 08, 2022 12:55pm
If they follow the same pattern as the last 7 newsletters it will be a Monday or a Tuesday. But there's no guarantee they will follow the same pattern, and there's not even any guarantee it will be released by next week! As this is a very important news release they're probably giving the timing a lot of thought and want to take full advantage of the impact it could have. Maybe they ...more  
Comment by enriquesuave on Mar 08, 2022 1:04pm
I perfectly agree there, as they are maybe waiting for more data 3, 6, 9 and 12 months assessments.  I guess it could sometimes take a bit more time,  My feeling is possibly this week still or if not then next week. However we are all guessing, but we at least know it's "soon".
Comment by 99942Apophis on Mar 08, 2022 1:54pm
Good to see of a very optimistic opinion by so many here of what this Newsletter represents to the company & us the shareholders. Funny I sort of feel like a kid again " are we there yet? " enriquesuave wrote  I perfectly agree there, as they are maybe waiting for more data 3, 6, 9 and 12 months assessments.  I guess it could sometimes take a bit more time,  My ...more  
Comment by CancerSlayer on Mar 08, 2022 3:31pm
Never liked the idea of a quarterly newsletter...prefer they just report material info as it comes & important data when appropriate.  Clinical trials & the gathering of data certainly don't operate on a quarterly basis.  The intention may have been to avoid long or unpredictable periods of silence, but such reporting simply sets you up for downside delays & the downside ...more  
Comment by rodrabal on Mar 08, 2022 4:43pm
Yes I agree with you. Withholding information in not good. Better to release every result as they receive it.Get the share price moving up with each piece of news and get some momentum going. Waiting three months at a time ,people just sell and move on. Because they know there will be no more news for three months
Comment by ScienceFirst on Mar 08, 2022 5:25pm
Another armchair quarterback that doesn't know how things work.   TLT doesn't have access to the data in real time.  And they have quarterly meetings with the CRO. __________________ rodrabal - (3/8/2022 4:43:57 PM)  RE:RE:RE:RE:RE:Reading the tea leaves... Yes I agree with you. Withholding information in not good. Better to release every result as ...more  
Comment by winr88 on Mar 08, 2022 5:05pm
My take on the newsletter.  Timing is not the issue with this newsletter. This could be the most important newsletter released by Theralase ever, since it will confirm what we shareholders and many watching have been waiting for......25 completed trial results and with a high CR percentage. This one needs accuracy, tranparency and understanding enough to excite the market into buying shares. ...more  
Comment by ScienceFirst on Mar 08, 2022 5:37pm
Nobody can guess results of individual patients in advance.  Nobody at TLT, nobody anywhere. The only thing we know is that our molecule works (4 patients cancer free) and that it works (CR) for 70% of a sample from treatment day to 180 days for 10 optimized patients.  Let's see if, for those 7 out of 10, the trend continued.  That would spell DURABILITY, so increase our ...more  
Comment by langosta on Mar 08, 2022 6:45pm
With only 48,500 traded on the venture it's easy to see that folks are hanging on for the next NR/ Newsletter, whatever you want to call it.
Comment by floatinketucky on Mar 30, 2022 9:49am
At this point I think we call up A PR and not a quarterly
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250